In 2011, a wayward cell culture revolutionized drug development and research. Dr. Madeline Lancaster, a cell biologist then based at the Institute of Molecular Biotechnology in Vienna, was working on culturing embryonic stem cells into circular neural cell arrangements when she noticed a botched batch acting strangely. As though following some omniscient signal, the cells joined together in synchronized agreement, slowly organizing into a pea-sized segment of neural circuitry: a lab-grown bit of brain.

Research conducted by Lancaster and her colleague Juergen Knoblich, as well as Yoshiki Sasasi at Kyoto University Graduate School of Medicine, identified the cause and applications of this phenomenon. By activating various signaling pathways with a cocktail of growth factors in a 3D extracellular matrix or media, scientists can manipulate either embryonic or induced pluripotent stem cells to generate cells that self-organize into functional tissue. The result is kernel-sized “ organoids ” reflective of tissue grown in a live human.

Today, lab-grown organoids substantiate entire areas of research, providing golden alternatives to animal testing and organ donation. Organoids have changed the game by facilitating disease modeling, toxic drug screening, and therapy development. Advancements in countless projects can be attributed to foundational organoid trials, including cystic fibrosis modeling, regenerative liver therapy, and anti-cancer drug response research .

Just as this technology reaches peak velocity, however, many are calling to pump the brakes and consider the impending future. Following the science’s trajectory, it is possible we may one day be able to grow functional, living brains out of a dish. To what end can we utilize this organism and at what point do we care? Of all ethical borders science treads, the question of how to classify organoid brains poses a critical crossroads, threatening to expose the human insecurity of unremarkable consciousness and lineate domains between bodies and souls.

A meeting held in Northern California in January 2026 aimed to brainstorm contentions surrounding these issues. The event was hosted by Dr. Sergiu Pașca, a researcher from Stanford University investigating pain pathways in brain organoids, and attended by bioethicists, researchers, and journalists.

The panel covered an important question: at what point in organoid development would the specimen attain human capacities? In other words, when should one start treating the organoid as a being rather than a tool? This becomes a more pressing issue with the introduction of combination organoids, or assembloids. Assembloids connect organoids into more complex fractions of an organ, bringing them a step closer in appearance to living beings.

While the panel did not decide on a firm boundary of consciousness, they recognized essential awareness circuitry as a necessary indicator. Take Pasca’s pain pathway research: as the assembloids are disconnected from a pathway for “emotional aversion,” there is no potential for their suffering. The mere association of the neural signal pathway with pain does not mean the organoids are in pain. This highlights the incomplete nature of organoids, emphasizing that their disconnectedness and isolated existence safeguard them against suffering, or real consciousness.

With organoids still in the early stages of development, researchers are confident no ethical lines have yet been crossed. That said, the technology is rapidly improving; hopefully alongside our understanding of consciousness.

As the panel ended, there was a clear consensus over the need to keep the public informed. Public and private institutions in the US all demand certain regulations to reign in unfettered scientific ambition. Ultimately, however, as organoid technology improves and these issues become more urgent, it becomes a public responsibility to decide the ethical limitations of science.